分子影像学杂志2025，Vol.48Issue(6)：776-780,5.DOI:10.12122/j.issn.1674-4500.2025.06.18
靶向碳酸酐酶IX的放射性药物的研究进展
Research progress of radiopharmaceuticals targeting carbonic anhydrase IX
谢家建 1冯悦 1张慧慧 1蔡亮1
作者信息
- 1. 重庆医科大学附属第二医院核医学科,重庆 400010
- 折叠
摘要
Abstract
The tumor microenvironment plays an important role in tumorigenesis,development,metastasis,and drug sensitivity.Carbonic anhydrase IX(CAIX)is a metalloenzyme that is highly expressed in certain tumor microenvironments and is closely related to tumor cell genesis,development and drug resistance.Its high expression in tumors and low expression in normal tissues makes it a potential target for the diagnosis and treatment of a variety of tumors.With the in-depth research on antitumor drugs and radionuclide-targeted therapy targeting CAIX,the detection of CAIX expression using noninvasive radiopharmaceuticals has become more urgent in order to meet the strategy of diagnostic and therapeutic integration.In this paper,we summarize and review the research on CAIX-targeting radiopharmaceuticals in recent years,analyze and summarize the advantages and disadvantages of monoclonal antibodies,small molecules and peptides,as well as the prospects of their clinical application,so as to optimize the structure of the drugs,reduce the side effects and meet the clinical needs,and to accelerate the clinical application of these drugs.关键词
碳酸酐酶IX/肾透明细胞癌/放射性核素药物/综述Key words
carbonic anhydrase/clear cell renal cell carcinoma/radiopharmaceuticals/review引用本文复制引用
谢家建,冯悦,张慧慧,蔡亮..靶向碳酸酐酶IX的放射性药物的研究进展[J].分子影像学杂志,2025,48(6):776-780,5.
